NEW YORK (GenomeWeb) – Predicine announced today that it has signed a deal under which it will co-promote its next-generation sequencing-based liquid biopsy cancer diagnostics in China with Shanghai-based CloudHealth Genomics.

Under the terms of the deal, CloudHealth will provide clinical genetic testing infrastructure and sequencing capacity in China for Predicine's PrediSeq cell-free DNA NGS cancer diagnostics, which are expected to launch mid-year, as well as additional tests that are slated for commercialization in "the upcoming year," the firms said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.